TY  - JOUR
AU  - Serrano, César
AU  - García-Del-Muro, Xavier
AU  - Valverde, Claudia
AU  - Sebio, Ana
AU  - Durán, José
AU  - Manzano, Aránzazu
AU  - Pajares, Isabel
AU  - Hindi, Nadia
AU  - Landolfi, Stefania
AU  - Jiménez, Laura
AU  - Rubió-Casadevall, Jordi
AU  - Estival, Anna
AU  - Lavernia, Javier
AU  - Safont, María José
AU  - Pericay, Carles
AU  - Díaz-Beveridge, Roberto
AU  - Martínez-Marín, Virginia
AU  - Vicente-Baz, David
AU  - Vivancos, Ana
AU  - Hernández-Losa, Javier
AU  - Arribas, Joaquín
AU  - Carles, Joan
PY  - 2018
DO  - 10.1634/theoncologist.2018-0032
UR  - http://hdl.handle.net/10668/12858
T2  - The oncologist
AB  - Oncogenic KIT/PDGFRA signaling inhibition with imatinib achieves disease control in most patients with advanced/metastatic gastrointestinal stromal tumor (GIST), but resistance eventually develops after 20-24 months. Notably, a small subset of these...
LA  - en
KW  - Gastrointestinal stromal tumor
KW  - Imatinib mesylate
KW  - Long‐term
KW  - c‐KIT
KW  - Adult
KW  - Antineoplastic Agents
KW  - Case-Control Studies
KW  - Disease Progression
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Gastrointestinal Neoplasms
KW  - Gastrointestinal Stromal Tumors
KW  - Humans
KW  - Imatinib Mesylate
KW  - Male
KW  - Middle Aged
KW  - Prognosis
KW  - Progression-Free Survival
KW  - Sarcoma
KW  - Time Factors
TI  - Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
TY  - research article
VL  - 24
ER  -